Yew Woon Chia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yew Woon Chia has a total of 196 co-authors. Here are the top co-authors by number of shared publications:
- Jonathan Yap
National Heart Centre Singapore
4 shared publications Shir Lynn Lim
Yong Loo Lin School of Medicine, National University of Singapore, Singapore
3 shared publications- Shir Lynn Lim
National University Heart Centre Singapore
3 shared publications - Calvin J. Chiew
National Centre for Infectious Diseases, Singapore, Singapore
2 shared publications - David Chien Lye
National Centre for Infectious Diseases, Singapore, Singapore
2 shared publications Kelvin Bryan Tan
National Centre for Infectious Diseases, Singapore
2 shared publications
Latest Publications
- Open Access
- 26 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (19) , 7492
Beyond Blood Pressure: The Role of Flow Parameters and Biomarkers of Hypoperfusion in Cardiogenic Shock
Cardiogenic shock (CS) remains a heterogeneous syndrome with persistently high mortality across acute myocardial infarction, decompensated heart failure, and post-cardiotomy states. Blood pressure, the most commonly used marker of hemodynamic status, is the product of cardiac output and systemic vascular resistance and can be preserved by compensatory vasoconstriction even as flow and tissue perfusion deteriorate. This review examines the evidence for measuring flow-derived hemodynamic parameters and biomarkers of hypoperfusion, rather than relying on pressure alone, to risk-stratify and inform therapy in CS. We propose a practical framework that distinguishes blood pressure targets, measured native flow, device-generated flow, and perfusion biomarkers, and that separates prognostic association from demonstrated treatment-guiding utility, since these are frequently conflated in the existing literature. We summarize data on pulmonary artery catheter-derived cardiac output and cardiac index, cardiac power output and index, the pulmonary artery pulsatility index, transpulmonary thermodilution and other advanced hemodynamic monitoring methods, echocardiographic flow assessment, and perfusion biomarkers including lactate, lactate clearance, and multimarker scores. We review how these parameters are incorporated into the Society for Cardiovascular Angiography and Interventions (SCAI) SHOCK staging and protocols for initiating, titrating, and weaning mechanical circulatory support (Impella, veno-arterial extracorporeal membrane oxygenation), including combined ECPELLA strategies, and we discuss the contemporary randomized trials most relevant to this field, DanGer Shock, ECLS-SHOCK, and ECMO-CS. We also examine how cardiogenic shock etiology and hemodynamic phenotype (e.g., right ventricle-predominant, cardiorenal, cardiometabolic) modify the interpretation and likely generalizability of these parameters. We conclude that integrating flow and perfusion markers with pressure provides a more complete, if not yet fully validated as treatment-guiding, picture of shock severity, while highlighting the continued scarcity of trials that test monitoring strategies themselves rather than the devices they inform.
- 26 September 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (19) , 7492
Open AccessBeyond Blood Pressure: The Role of Flow Parameters and Biomarkers of Hypoperfusion in Cardiogenic Shock
Cardiogenic shock (CS) remains a heterogeneous syndrome with persistently high mortality across acute myocardial infarction, decompensated heart failure, and post-cardiotomy states. Blood pressure, the most commonly used marker of hemodynamic status, is the product of cardiac output and systemic vascular resistance and can be preserved by compensatory vasoconstriction even as flow and tissue perfusion deteriorate. This review examines the evidence for measuring flow-derived hemodynamic parameters and biomarkers of hypoperfusion, rather than relying on pressure alone, to risk-stratify and inform therapy in CS. We propose a practical framework that distinguishes blood pressure targets, measured native flow, device-generated flow, and perfusion biomarkers, and that separates prognostic association from demonstrated treatment-guiding utility, since these are frequently conflated in the existing literature. We summarize data on pulmonary artery catheter-derived cardiac output and cardiac index, cardiac power output and index, the pulmonary artery pulsatility index, transpulmonary thermodilution and other advanced hemodynamic monitoring methods, echocardiographic flow assessment, and perfusion biomarkers including lactate, lactate clearance, and multimarker scores. We review how these parameters are incorporated into the Society for Cardiovascular Angiography and Interventions (SCAI) SHOCK staging and protocols for initiating, titrating, and weaning mechanical circulatory support (Impella, veno-arterial extracorporeal membrane oxygenation), including combined ECPELLA strategies, and we discuss the contemporary randomized trials most relevant to this field, DanGer Shock, ECLS-SHOCK, and ECMO-CS. We also examine how cardiogenic shock etiology and hemodynamic phenotype (e.g., right ventricle-predominant, cardiorenal, cardiometabolic) modify the interpretation and likely generalizability of these parameters. We conclude that integrating flow and perfusion markers with pressure provides a more complete, if not yet fully validated as treatment-guiding, picture of shock severity, while highlighting the continued scarcity of trials that test monitoring strategies themselves rather than the devices they inform.
- Open Access
- 9 September 2026
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 19 (10)
Associations of age, COVID-19 vaccination, and SARS-CoV-2 infection history with health-related quality of life in a community-based longitudinal cohort in Singapore
- 9 September 2026
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 19 (10)
Open AccessAssociations of age, COVID-19 vaccination, and SARS-CoV-2 infection history with health-related quality of life in a community-based longitudinal cohort in Singapore
- Open Access
- 27 July 2026
- Published by Wolters Kluwer Health in Singapore Medical Journal
- Vol. 67 (7) , 427-441
Singapore Post-cardiac Arrest Care Guidelines 2026
A robust chain of survival is important for achieving positive outcomes following out-of-hospital cardiac arrest, which continues to pose a substantial public health challenge in Singapore. Although improvements have been made in prehospital resuscitation and survival to hospital admission, further progress is required for survival to hospital discharge and neurological recovery. This underscores the urgent need to strengthen post-cardiac arrest care—the sixth link in the chain of survival—to optimise outcomes for patients admitted to the intensive care unit after return of spontaneous circulation. This review builds on earlier recommendations of the National Targeted Temperature Management Workgroup (2017) and the National Post-Cardiac Arrest and Survivorship Workgroup (2021), providing an updated summary of post-cardiac arrest management and practical guidance for clinicians treating resuscitated cardiac arrest patients in the intensive care unit.
- 27 July 2026
- Published by Wolters Kluwer Health in Singapore Medical Journal
- Vol. 67 (7) , 427-441
Open AccessSingapore Post-cardiac Arrest Care Guidelines 2026
A robust chain of survival is important for achieving positive outcomes following out-of-hospital cardiac arrest, which continues to pose a substantial public health challenge in Singapore. Although improvements have been made in prehospital resuscitation and survival to hospital admission, further progress is required for survival to hospital discharge and neurological recovery. This underscores the urgent need to strengthen post-cardiac arrest care—the sixth link in the chain of survival—to optimise outcomes for patients admitted to the intensive care unit after return of spontaneous circulation. This review builds on earlier recommendations of the National Targeted Temperature Management Workgroup (2017) and the National Post-Cardiac Arrest and Survivorship Workgroup (2021), providing an updated summary of post-cardiac arrest management and practical guidance for clinicians treating resuscitated cardiac arrest patients in the intensive care unit.
- Open Access
- 3 June 2026
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 15 (7) , 1955-1976
Prior SGLT2 Inhibitor and Metformin Use and Risk of Long COVID in Type 2 Diabetes: A Nationwide Population-Based Cohort Study
Introduction Patients with type 2 diabetes mellitus (T2DM) are at increased risk of post-acute sequelae after COVID-19 (PASC). Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and metformin may have systemic benefits beyond glycemic control. We evaluated the impact of prior SGLT2i and metformin use on the risk of post-acute COVID-19 complications. Methods We conducted a retrospective, population-based cohort study using national healthcare claims databases, from July 1, 2021 to February 28, 2023. Cohorts were stratified based on SGLT2i or metformin, against patients had not received these medications. Overlap weighting was applied to adjust for baseline differences in demographics, vaccination status, comorbidities, and prior healthcare utilization. Competing-risks regression models were used to assess differences in the risk of long-COVID outcomes between 31 and 300 days post-infection. Results Among 71,698 patients with T2DM, 22,501 (31.4%) had prior SGLT2i use, and 66,792 (93.1%) had prior metformin use. Compared with non-SGLT2i users, patients treated with SGLT2i had a significantly lower risk of neurological sequelae (aHR = 0.60 [0.45–0.81]), particularly memory and cognitive impairment (aHR = 0.63 [0.41–0.98]). SGLT2i was also associated with a reduced risk of post-acute symptoms (aHR = 0.87 [0.77–0.99]). Metformin use was associated with significantly lower risk of composite post-acute outcomes (aHR = 0.80 [0.68–0.96]) and post-acute symptoms (aHR = 0.77 [0.63–0.93]). Amongst patients on metformin, the addition of SGLT2i further lowered the risk of neurological sequelae (aHR = 0.81 [0.71–0.93]) and composite symptoms (aHR 0.87 [0.76–0.99]). Conclusion SGLT2i and metformin use were associated with a lower risk of PASC and post-acute symptoms. There may be additional protective benefits when both agents are used concurrently.
- 3 June 2026
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 15 (7) , 1955-1976
Open AccessPrior SGLT2 Inhibitor and Metformin Use and Risk of Long COVID in Type 2 Diabetes: A Nationwide Population-Based Cohort Study
Introduction Patients with type 2 diabetes mellitus (T2DM) are at increased risk of post-acute sequelae after COVID-19 (PASC). Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and metformin may have systemic benefits beyond glycemic control. We evaluated the impact of prior SGLT2i and metformin use on the risk of post-acute COVID-19 complications. Methods We conducted a retrospective, population-based cohort study using national healthcare claims databases, from July 1, 2021 to February 28, 2023. Cohorts were stratified based on SGLT2i or metformin, against patients had not received these medications. Overlap weighting was applied to adjust for baseline differences in demographics, vaccination status, comorbidities, and prior healthcare utilization. Competing-risks regression models were used to assess differences in the risk of long-COVID outcomes between 31 and 300 days post-infection. Results Among 71,698 patients with T2DM, 22,501 (31.4%) had prior SGLT2i use, and 66,792 (93.1%) had prior metformin use. Compared with non-SGLT2i users, patients treated with SGLT2i had a significantly lower risk of neurological sequelae (aHR = 0.60 [0.45–0.81]), particularly memory and cognitive impairment (aHR = 0.63 [0.41–0.98]). SGLT2i was also associated with a reduced risk of post-acute symptoms (aHR = 0.87 [0.77–0.99]). Metformin use was associated with significantly lower risk of composite post-acute outcomes (aHR = 0.80 [0.68–0.96]) and post-acute symptoms (aHR = 0.77 [0.63–0.93]). Amongst patients on metformin, the addition of SGLT2i further lowered the risk of neurological sequelae (aHR = 0.81 [0.71–0.93]) and composite symptoms (aHR 0.87 [0.76–0.99]). Conclusion SGLT2i and metformin use were associated with a lower risk of PASC and post-acute symptoms. There may be additional protective benefits when both agents are used concurrently.
- Open Access
- 31 October 2025
- Published by Elsevier in Resuscitation
- Vol. 217, 110878
The cost-effectiveness of mild hypercapnia after out-of-hospital cardiac arrest: a health economic evaluation alongside the TAME study
- 31 October 2025
- Published by Elsevier in Resuscitation
- Vol. 217, 110878
Open AccessThe cost-effectiveness of mild hypercapnia after out-of-hospital cardiac arrest: a health economic evaluation alongside the TAME study
- Open Access
- 30 April 2025
- Published by Academy of Medicine, Singapore in Annals of the Academy of Medicine, Singapore
- Vol. 54 (5) , 270-282
Omicron SARS-CoV-2 outcomes in vaccinated individuals with heart failure and ischaemic heart disease
Introduction: Outcomes after SARS-CoV 2 Omicron infection in patients with heart failure (HF) and ischaemic heart disease (IHD) remain poorly defined. Method: In a highly vaccinated cohort of adult Singapore citizens and permanent residents, we used Cox proportional hazards models (adjusted for sociodemographic variables and comorbidities) to compare the risks of Omicron infection, COVID 19–related hospitalisation, and severe COVID 19 between individuals with HF or IHD and matched controls without these conditions. Results: From national databases, we identified 15,426 HF patients matched 1:~3 to 41,221 controls, and 110,442 IHD patients matched 1:~2 to 223,843 controls. Over 80% of HF and IHD patients had received at least 3 vaccine doses. During the Omicron-predominant period, both HF and IHD cohorts demonstrated higher adjusted risks of COVID 19 hospitalisation compared with matched controls (HF: aHR 1.77, 95% confidence interval [CI] 1.65–1.90; IHD: aHR 1.21, 95% CI 1.17–1.26). Among those with at least 1 HF- or IHD-related admission in the prior year, hospitalisation risk was further elevated (HF: aHR 1.27, 95% CI 1.13–1.42; IHD: aHR 1.11, 95% CI 1.01–1.23). Receipt of ≥3 vaccine doses was associated with substantially lower risk of severe COVID 19 versus only 2 doses (HF: aHR 0.35, 95% CI 0.28–0.43; IHD: aHR 0.27, 95% CI 0.23–0.32). A fourth dose conferred additional reductions in infection and adverse outcomes, though CIs for infection overlapped with those for 3 doses. Conclusion: During Omicron predominance, HF and IHD patients experienced greater risk of COVID-19 hospitalisation and severe COVID 19 versus matched controls. Booster vaccinations attenuated these risks. Individuals with recent HF/IHD admissions should be prioritised for receipt of booster vaccine doses.
- 30 April 2025
- Published by Academy of Medicine, Singapore in Annals of the Academy of Medicine, Singapore
- Vol. 54 (5) , 270-282
Open AccessOmicron SARS-CoV-2 outcomes in vaccinated individuals with heart failure and ischaemic heart disease
Introduction: Outcomes after SARS-CoV 2 Omicron infection in patients with heart failure (HF) and ischaemic heart disease (IHD) remain poorly defined. Method: In a highly vaccinated cohort of adult Singapore citizens and permanent residents, we used Cox proportional hazards models (adjusted for sociodemographic variables and comorbidities) to compare the risks of Omicron infection, COVID 19–related hospitalisation, and severe COVID 19 between individuals with HF or IHD and matched controls without these conditions. Results: From national databases, we identified 15,426 HF patients matched 1:~3 to 41,221 controls, and 110,442 IHD patients matched 1:~2 to 223,843 controls. Over 80% of HF and IHD patients had received at least 3 vaccine doses. During the Omicron-predominant period, both HF and IHD cohorts demonstrated higher adjusted risks of COVID 19 hospitalisation compared with matched controls (HF: aHR 1.77, 95% confidence interval [CI] 1.65–1.90; IHD: aHR 1.21, 95% CI 1.17–1.26). Among those with at least 1 HF- or IHD-related admission in the prior year, hospitalisation risk was further elevated (HF: aHR 1.27, 95% CI 1.13–1.42; IHD: aHR 1.11, 95% CI 1.01–1.23). Receipt of ≥3 vaccine doses was associated with substantially lower risk of severe COVID 19 versus only 2 doses (HF: aHR 0.35, 95% CI 0.28–0.43; IHD: aHR 0.27, 95% CI 0.23–0.32). A fourth dose conferred additional reductions in infection and adverse outcomes, though CIs for infection overlapped with those for 3 doses. Conclusion: During Omicron predominance, HF and IHD patients experienced greater risk of COVID-19 hospitalisation and severe COVID 19 versus matched controls. Booster vaccinations attenuated these risks. Individuals with recent HF/IHD admissions should be prioritised for receipt of booster vaccine doses.
- 20 June 2024
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 30 (10) , 1319-1326
Long-term cardiovascular, cerebrovascular, and thrombotic complications after SARS-CoV-2-Omicron infection: a retrospective cohort study
- 20 June 2024
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 30 (10) , 1319-1326
Long-term cardiovascular, cerebrovascular, and thrombotic complications after SARS-CoV-2-Omicron infection: a retrospective cohort study
- Open Access
- 24 April 2024
- Published by Radcliffe Medical Media Ltd in Journal of Asian Pacific Society of Cardiology
- Vol. 3
Asian Pacific Society of Cardiology Consensus Statements on the Diagnosis and Management of Acute MI-Cardiogenic Shock and Endorsed by the Asian Pacific Society of Interventional Cardiology
In the Asia-Pacific region, acute MI (AMI) is associated with a high rate of cardiogenic shock (CS), which increases the risk of mortality several-fold. The management of AMI-CS in the region is heterogeneous and lacks consensus. Hence, an Asian Pacific Society of Cardiology working group developed consensus recommendations on the management of AMI-CS in the Asia-Pacific region. The Asian Pacific Society of Cardiology expert panel reviewed and appraised the available evidence using the Grading of Recommendations Assessment, Development, and Evaluation system. Consensus recommendations were developed and put to an online vote. Consensus was reached when 80% of votes for a given recommendation were ‘agree’ or ‘neutral.’ The resulting statements, which have been endorsed by the Asian Pacific Society of Interventional Cardiology and affirmed by the Society for Cardiovascular Angiography and Interventions, provide guidance on the diagnosis, assessment and treatment of patients with AMI-CS among clinical practitioners in the region.
- 24 April 2024
- Published by Radcliffe Medical Media Ltd in Journal of Asian Pacific Society of Cardiology
- Vol. 3
Open AccessAsian Pacific Society of Cardiology Consensus Statements on the Diagnosis and Management of Acute MI-Cardiogenic Shock and Endorsed by the Asian Pacific Society of Interventional Cardiology
In the Asia-Pacific region, acute MI (AMI) is associated with a high rate of cardiogenic shock (CS), which increases the risk of mortality several-fold. The management of AMI-CS in the region is heterogeneous and lacks consensus. Hence, an Asian Pacific Society of Cardiology working group developed consensus recommendations on the management of AMI-CS in the Asia-Pacific region. The Asian Pacific Society of Cardiology expert panel reviewed and appraised the available evidence using the Grading of Recommendations Assessment, Development, and Evaluation system. Consensus recommendations were developed and put to an online vote. Consensus was reached when 80% of votes for a given recommendation were ‘agree’ or ‘neutral.’ The resulting statements, which have been endorsed by the Asian Pacific Society of Interventional Cardiology and affirmed by the Society for Cardiovascular Angiography and Interventions, provide guidance on the diagnosis, assessment and treatment of patients with AMI-CS among clinical practitioners in the region.
- 29 November 2023
- Published by Springer Nature
- p. 273-283
Right Ventricular Failure in Pulmonary Embolism: The Forgotten Chamber—When in Trouble, Go Back to Basics
- 29 November 2023
- Published by Springer Nature
- p. 273-283
Right Ventricular Failure in Pulmonary Embolism: The Forgotten Chamber—When in Trouble, Go Back to Basics
- Open Access
- 5 July 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (13) , 4497
Blood Pressure Targets for Out-of-Hospital Cardiac Arrest: A Systematic Review and Meta-Analysis
Background: With ideal mean arterial pressure (MAP) targets in resuscitated out-of-hospital cardiac arrest (OHCA) patients unknown, we performed a meta-analysis of randomised controlled trials (RCTs) to compare the effects of higher versus lower MAP targets. Methods: We searched four databases until 1 May 2023 for RCTs reporting the effects of higher MAP targets (>70 mmHg) in resuscitated OHCA patients and conducted random-effects meta-analyses. The primary outcome was mortality while secondary outcomes were neurological evaluations, arrhythmias, acute kidney injury, and durations of mechanical ventilation and ICU stay. We conducted inverse-variance weighted strata-level meta-regression against a proportion of non-survivors to assess differences between reported MAPs. We also conducted a trial sequential analysis of RCTs. Results: Four RCTs were included. Higher MAP was not associated with reduced mortality (OR: 1.09, 95%-CI: 0.84 to 1.42, p = 0.51), or improved neurological outcomes (OR: 0.99, 95%-CI: 0.77 to 1.27, p = 0.92). Such findings were consistent despite additional sensitivity analyses. Our robust variance strata-level meta-regression revealed no significant associations between mean MAP and the proportion of non-survivors (B: 0.029, 95%-CI: −0.023 to 0.081, p = 0.162), and trial sequential analysis revealed no meaningful survival benefit for higher MAPs. Conclusions: A higher MAP target was not significantly associated with improved mortality and neurological outcomes in resuscitated OHCA patients.
- 5 July 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (13) , 4497
Open AccessBlood Pressure Targets for Out-of-Hospital Cardiac Arrest: A Systematic Review and Meta-Analysis
Background: With ideal mean arterial pressure (MAP) targets in resuscitated out-of-hospital cardiac arrest (OHCA) patients unknown, we performed a meta-analysis of randomised controlled trials (RCTs) to compare the effects of higher versus lower MAP targets. Methods: We searched four databases until 1 May 2023 for RCTs reporting the effects of higher MAP targets (>70 mmHg) in resuscitated OHCA patients and conducted random-effects meta-analyses. The primary outcome was mortality while secondary outcomes were neurological evaluations, arrhythmias, acute kidney injury, and durations of mechanical ventilation and ICU stay. We conducted inverse-variance weighted strata-level meta-regression against a proportion of non-survivors to assess differences between reported MAPs. We also conducted a trial sequential analysis of RCTs. Results: Four RCTs were included. Higher MAP was not associated with reduced mortality (OR: 1.09, 95%-CI: 0.84 to 1.42, p = 0.51), or improved neurological outcomes (OR: 0.99, 95%-CI: 0.77 to 1.27, p = 0.92). Such findings were consistent despite additional sensitivity analyses. Our robust variance strata-level meta-regression revealed no significant associations between mean MAP and the proportion of non-survivors (B: 0.029, 95%-CI: −0.023 to 0.081, p = 0.162), and trial sequential analysis revealed no meaningful survival benefit for higher MAPs. Conclusions: A higher MAP target was not significantly associated with improved mortality and neurological outcomes in resuscitated OHCA patients.